Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Trends in Cancer Research   Volumes    Volume 15 
Stereotactic body radiotherapy in the treatment of advanced non-small cell lung cancer patients with oligoprogression during immunotherapy
Miguel J. Sotelo, Alejandro Riquelme, Stella Arambulo, Ana Calle, Rodrigo Motta, Santiago Cabezas-Camarero
Pages: 91 - 100
Number of pages: 10
Trends in Cancer Research
Volume 15 

Copyright © 2020 Research Trends. All rights reserved

Immune checkpoint inhibitors (ICIs) improve survival in patients with metastatic non-small cell lung cancer (NSCLC), but, unfortunately, only a minority clearly benefits from ICIs, and treatment options after progression to these agents are limited and not very effective. Patients with oligometastatic disease may benefit from local treatments such as radiotherapy, achieving better local control rates, delaying progression and improving survival. Stereotactic body radiotherapy (SBRT) allows to deliver high radiation doses, with much less toxicity. Furthermore, radiotherapy has several immunomodulatory effects that could enhance the activity of ICIs and this synergy seems to be improved with SBRT. Our aim was to review the evidence supporting the use of SBRT in patients with metastatic NSCLC with oligoprogressive disease after an initial benefit with ICIs.
View Full Article  


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms